Treatment of Chronic-Phase Chronic Myeloid Leukemia in Patients Randomized to Dasatinib or Imatinib after Suboptimal Responses to Three Months of Imatinib Therapy: Final 5-Year Results from DASCERN

DASCERN was a prospective, Phase IIb, randomized trial evaluating a switch to dasatinib in patients who have not achieved early molecular response after three months of treatment with first-line imatinib.